Trial Profile
Pharmacodynamics of Pre-Operative PD1 Checkpoint Blockade and Receptor Activator of NFkB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) - a phase 1B/2 trial
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Sep 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Nivolumab (Primary) ; Calcium; Vitamin D
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Pharmacodynamics
- Acronyms POPCORN
- 19 Dec 2019 Trial design published in the Trials.
- 20 Sep 2019 Status changed from not yet recruiting to recruiting.
- 10 Jul 2018 New trial record